Results 51 to 60 of about 38,488 (237)

Remaining Questions about Clinical Variola Major

Emerging Infectious Diseases, 2011
After the recent summary of World Health Organization–authorized research on smallpox, several clinical issues remain. This policy review addresses whether early hemorrhagic smallpox is disseminated intravascular coagulation and speculates about the ...
J. Michael Lane
doaj   +1 more source

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +3 more sources

Vaccinia virus-based vector against infectious diseases and tumors

Human Vaccines & Immunotherapeutics, 2021
Vaccinia virus was used to prevent smallpox. After the World Health Organization declared smallpox extinct, vaccinia virus has been explored for the development of vaccines against a variety of infectious diseases.
Ziling Zhang, Lanlan Dong, Chen Zhao, Peiyong Zheng, Xiaoyan Zhang, Jianqing Xu   +5 more
doaj   +1 more source

Lawrence O. Gostin on Biosecurity Policy: Are We Safer Today? [PDF]

, 2008
World-acclaimed authority Lawrence O. Gostin analyzes biosecurity policy since 9/11. He begins with the question: Are we safer now? Then comes a review of biosecurity legislation, followed by discussion of planning to deal with specific diseases and the ...
Gostin, Lawrence O.
core   +1 more source

Phase-out of smallpox vaccination and the female/male HIV-1 prevalence ratio: an ecological study from Guinea-Bissau

BMJ Open, 2019
Objective In Guinea-Bissau, West Africa, we observed that having a smallpox vaccination scar was associated with lower HIV-1 prevalence, more strongly for women than men.
Marie Villumsen, Peter Aaby, Amabelia Rodrigues, Andreas Rieckmann, Christine Benn, Bo Langhoff Hønge, Signe Sørup, Zacarias Jose da Silva, Hilton Whittle   +8 more
doaj   +1 more source

Serological Immunity to Smallpox in New South Wales, Australia

Viruses, 2020
The re-emergence of smallpox is an increasing and legitimate concern due to advances in synthetic biology. Vaccination programs against smallpox using the vaccinia virus vaccine ceased with the eradication of smallpox and, unlike many other countries ...
Valentina Costantino, Mallory J. Trent, John S. Sullivan, Mohana P. Kunasekaran, Richard Gray, Raina MacIntyre   +5 more
doaj   +1 more source

Who invented vaccination? [PDF]

, 2011
Edward Jenner, whose ‘Inquiry’ (1798)1 was the first published report of vaccination against smallpox, is widely seen as the inventor of vaccination. However, other individuals could lay claim to this title, notably his contemporaries, Benjamin Jesty and
Jesty, Robert, Williams, Gareth
core  

Monkeypox in humans – the review

Journal of Education, Health and Sport, 2022
Monkeypox is an emerging zoonotic disease caused by the monkeypox virus with a presentation similar to smallpox. Being previously endemic to Africa, now the disease is spreading across the world, causing fear of a potential next pandemic.
Konrad Warchoł, Adam Jasiura , Kamila Giżewska, Aleksandra Wójcik , Sylwiusz Niedobylski   +4 more
doaj   +1 more source

Struggling to a monumental triumph : Re-assessing the final stages of the smallpox eradication program in India, 1960-1980 [PDF]

, 2007
The global smallpox program is generally presented as the brainchild of a handful of actors from the WHO headquarters in Geneva and at the agency's regional offices.
Basu, R. N, Bonne W, Bonne W, Brilliant L. B, Brilliant L. B, Dutta Mahendra, Dutta Mahendra, Grasset N, Grasset N, Grasset N, Grasset N, Grasset N, Grasset N. c, Greenough P, Gunaratne V.T.H, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Henderson D.A, Jungalwalla N.K, Mahler H, Maltseva N, Mani C, Naraindas Harish, Payne A.M.H, Pifer John M, Sanjoy Bhattacharya, Singh Mahendra   +33 more
core   +2 more sources

Approaches to Reduce Adverse Effect of Vaccinia Virus in Orally Immunized Mice

Проблемы особо опасных инфекций, 2016
Objective of the investigation was to model the adverse action of vaccinia virus (VV), caused by oral immunization of mice and to evaluate efficacy of its reduction, using therapeutic and prophylactic drugs. Materials and methods.
D. O. Galakhova, Ar. A. Sergeev, E. V. Shevtsova, Al. A. Sergeev, A. S. Zamedyanskaya, K. A. Titova, L. N. Shishkina, L. E. Bulychev, S. V. Borisevich, V. N. Podkuiko, A. P. Pirozhkov, A. V. Koval’Chuk, Ya. V. Polyansky, E. Yu. Vakhnov, V. V. Perekrest, V. A. Shevtsov, A. P. Agafonov, A. N. Sergeev   +17 more
doaj   +1 more source